Cloud migration to accelerate drug discovery with AWS

Owkin
AWS Migration Cloud Industry & Services
Publié le 23 mai 2024
iStock-1409117178

Context

Owkin is a leading biotechnology company specializing in the application of Artificial Intelligence (AI) and Machine Learning (ML) for drug discovery.

Owkin wishes to stablish a strong partnership with AWS, a pivotal step in Owkin's mission to focus on its core competency of developing high-value algorithms for advancing medical research and pharmaceutical development.

Owkin aims to significantly expand its market share and fully leverage the capabilities of AWS, particularly the AWS Marketplace and Amazon SageMaker platforms.

Aneo provided technical and organizational support to help Owkin effectively migrate to AWS.

The primary objective for ANEO was to lay a robust foundation for Owkin's migration and integration into AWS's ecosystem.

This migration include setting up a Landing Zone in AWS with a Hub-And-Spoke architecture.

Ready to change how you work?

In the spotlight

cas clients - bioptimus
Accelerating LLMs on AWS Cloud for bioinformatics
06 June 2024 Artificial intelligence
Industry & Services
Aneo supported a bioinformatics company specializing in genAI/LLMs, in optimizing its AWS cloud infrastructure and AI processes to accelerate drug discovery.
Voir plus
cas clients - deeplife
HPC Workload Migration and Optimization to AWS
23 May 2024 AWS Migration
Industry & Services
DeepLife develops novel approaches to drug discovery based on state-of art multi-omics data, machine learning, and system engineering.
Voir plus
cas clients - mnemo
Optimizing computing power for tomorrow's medicines with AWS
23 May 2024 AWS Migration
Industry & Services
As part of the design of tomorrow's medicines, Mnemo has a need to satisfy its requirements for intensive computing orchestration power of more than tens of thousands of instances on cloud computing grids.
Voir plus